Drug discovery using chemical systems biology: Identification of the protein-ligand binding network to explain the side effects of CETP inhibitors

PLoS Computational Biology

Volumn 5, Issue 5, 2009, Pages

  Xie, Li ^a   Li, Jerry ^b   Xie, Lei ^c   Bourne, Philip E ^a,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE CONTROL; DISEASES; LIGANDS; PROTEINS;

CHEMICAL SYSTEMS; CHOLESTERYL ESTER TRANSFER PROTEINS; COMBINATORIAL CONTROL; DRUG DISCOVERY; DRUG EFFECTS; LIGAND BINDING; PROTEIN INHIBITORS; PROTEIN LIGANDS; SIDE EFFECT; SYSTEMS BIOLOGY;

DRUG INTERACTIONS;

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ANACETRAPIB; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIVER RECEPTOR HOMOLOG 1; TORCETRAPIB; CELL RECEPTOR; CETP PROTEIN, HUMAN; CHOLESTEROL ESTER TRANSFER PROTEIN; LIGAND; PROTEOME;

ARTICLE; BINDING AFFINITY; DRUG PROTEIN BINDING; DRUG STRUCTURE; GENE MAPPING; GENE STRUCTURE; GENE TARGETING; HYPERTENSION; PROTEIN ANALYSIS; BIOLOGICAL MODEL; CELL PROLIFERATION; CLUSTER ANALYSIS; DRUG ANTAGONISM; DRUG DEVELOPMENT; DRUG EFFECT; GENE REGULATORY NETWORK; GENETIC DATABASE; INFLAMMATION; METHODOLOGY; PROTEIN BINDING; PROTEIN DOMAIN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STATISTICAL MODEL; SYSTEMS BIOLOGY;

ANTICHOLESTEREMIC AGENTS; CELL PROLIFERATION; CHOLESTEROL ESTER TRANSFER PROTEINS; CLUSTER ANALYSIS; DATABASES, GENETIC; DRUG DISCOVERY; GENE REGULATORY NETWORKS; INFLAMMATION; LIGANDS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEOME; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RENIN-ANGIOTENSIN SYSTEM; SYSTEMS BIOLOGY;

EID: 67049100457     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1000387     Document Type: Article

References (106)

1. Kuhn M, Campillos M, González P, Jensen LJ, Bork P (2008) Large-scale prediction of drug-target relationships. FEBS Lett 582: 1283-1290.
2. Weber A, Casini A, Heine A, Kuhn D, Supuran CT, et al. (2004) Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem 47: 550-557. (Pubitemid 38129713)
3. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, et al. (2007) Relating protein pharmacology by ligand chemistry. Nat Biotechnol 25: 197-206. (Pubitemid 46227119)
4. Xie L, Wang J, Bourne PE (2007) In silico elucidation of the molecular mechanism defining the adverse effect of selective estrogen receptor modulators. PLoS Comp Biol 3: e217. doi:10.1371/journal.pcbi.0030217.
5. Paolini GV, Shapland RH, van Hoorn WP, Mason JS, Hopkins AL (2006) Global mapping of pharmacological space. Nat Biotechnol 24: 805-815. (Pubitemid 44086621)
6. Zimmermann GR, Lehár J, Keith CT (2007) Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 12: 34-42. (Pubitemid 46014485)
7. O'Connor KA, Roth BL (2005) Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat Rev Drug Discov 4: 1005-1014.
8. Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3: 673-683. (Pubitemid 39173508)
9. Kennedy T (1997) Managing the drug discovery /development interface. Drug Discov Today 2: 436-444. (Pubitemid 27387353)
10. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK (2006) Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2: 458-466. (Pubitemid 44266307)
11. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P (2008) Drug target identification using side-effect similarity. Science 321: 263-266. (Pubitemid 351989100)
12. Bender A, Young DW, Jenkins JL, Serrano M, Mikhailov D, et al. (2007) Chemogenomic data analysis: prediction of small-molecule targets and the advent of biological fingerprint. Comb Chem High Throughput Screen 10: 719-731. (Pubitemid 350099316)
13. Jacoby E (2006) Chemogenomics: drug discovery's panacea? Mol Biosyst 2: 218-220.
14. Mestres J (2004) Computational chemogenomics approaches to systematic knowledge-based drug discovery. Curr Opin Drug Discov Devel 7: 304-313. (Pubitemid 44120947)
15. Rognan D (2007) Chemogenomic approaches to rational drug design. Br J Pharmacol 152: 38-52. (Pubitemid 47339898)
16. Savchuk NP, Balakin KV, Tkachenko SE (2004) Exploring the chemogenomic knowledge space with annotated chemical libraries. Curr Opin Chem Biol 8: 414-417. (Pubitemid 38993735)
17. Wuster A, Madan Babu M (2008) Chemogenomics and biotechnology. Trends Biotechnol 26: 252-258.
18. Hert, Keiser, Irwin, Oprea, Shoichet (2008) Quantifying the relationships among drug classes. J Chem Inf Model 48: 755-765.
19. Xie L, Bourne PE (2007) A robust and efficient algorithm for the shape description of protein structures and its application in predicting ligand binding sites. BMC Bioinformatics 8: S9. (Pubitemid 351833828)
20. Xie L, Bourne PE (2008) Detecting evolutionary relationships across existing fold space, using sequence order-independent profile-profile alignments. Proc Natl Acad Sci U S A 105: 5441-5446. (Pubitemid 351753882)
21. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, et al. (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357: 2109-2122. (Pubitemid 350146106)
22. Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cumiskey A-M, et al. (2008) Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 154: 1465-1473.
23. Howes LG, Kostner K (2007) The withdrawal of torcetrapib from drug development: implications for the future of drugs that alter HDL metabolism. Expert Opin Investig Drugs 16: 1509-1516. (Pubitemid 350028403)
24. Joy TR, Hegele RA (2008) The failure of torcetrapib: what have we learned? Br J Pharmacol 154: 1379-1381.
25. Kontush A, Guérin M, Chapman MJ (2008) Spotlight on HDL-raising therapies: insights from the torcetrapib trials. Nat Clin Pract Cardiovasc Med 5: 329-336. (Pubitemid 351761707)
26. Miura S, Matsuo Y, Kawamura A, Saku K (2005) JTT-705 blocks cell proliferation and angiogenesis through p38 kinase/p27(kip1) and Ras/ p21(waf1) pathways. Atherosclerosis 182: 267-275. (Pubitemid 41267194)
27. Jain AN (2007) Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search. J Comput Aided Mol Des 21: 281-306. (Pubitemid 46630055)
28. Zsoldos Z, Reid D, Simon A, Sadjad SB, Johnson AP (2007) eHiTS: a new fast, exhaustive flexible ligand docking system. J Mol Graph Model 26: 198-212. (Pubitemid 46977244)
29. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, et al. (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19: 1639-1662. (Pubitemid 128590223)
30. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Res 28: 235-242. (Pubitemid 30047768)
31. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, et al. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25: 3389-3402. (Pubitemid 27359211)
32. Finn RD, Tate J, Mistry J, Coggill PC, Sammut SJ, et al. (2008) The Pfam protein families database. Nucleic Acids Res 36: D281-D288. (Pubitemid 351149737)
33. Ye Y, Godzik A (2003) Flexible structure alignment by chaining aligned fragment pairs allowing twists. Bioinformatics 19: ii246-ii255. (Pubitemid 41296662)
34. Bensinger SJ, Tontonoz P (2008) Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454: 470-477.
35. Fernández JM, Hoffmann R, Valencia A (2007) iHOP web services. Nucleic Acids Res 35: W21-W26.
36. Schlicker A, Albrecht M (2008) FunSimMat: a comprehensive functional similarity database. Nucleic Acids Res 36: D434-D439. (Pubitemid 351149762)
37. Resnik P (1999) Semantic similarity in a taxonomy: an information-based measure and its application to problems of ambiguity in natural language. Artif Intell Res 11: 95-130. (Pubitemid 129628761)
38. Wang R, Lu Y, Wang S (2003) Comparative evaluation of 11 scoring functions for molecular docking. J Med Chem 46: 2287-2303. (Pubitemid 36637914)
39. Ferrara P, Gohlke H, Price DJ, Brooks CLI, Klebe G (2004) Assessing scoring functions for protein-ligand interactions. J Med Chem 47: 3032-3047. (Pubitemid 38702700)
40. Warren GL, Andrews CW, Capelli A-M, Clarke B, LaLonde J, et al. (2006) A critical assessment of docking programs and scoring functions. J Med Chem 49: 5912-5931. (Pubitemid 44484938)
41. Hopkins AL, Mason JS, Overington JP (2006) Can we rationally design promiscuous drugs? Curr Opin Struct Biol 16: 127-136.
42. Kuipers I, van der Harst P, Navis G, van Genne L, Morello F, et al. (2008) Nuclear hormone receptors as regulators of the renin-angiotensin- aldosterone system. Hypertension 51: 1442-1448.
43. Khovidhunkit W, Kim M-S, Memon RA, Shigenaga JK, Moser AH, et al. (2004) Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 45: 1169-1196. (Pubitemid 38802622)
44. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, et al. (1999) Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappa B and AP-1. J Biol Chem 274: 32048-32054. (Pubitemid 129503797)
45. Chung SW, Kang BY, Kim SH, Pak YK, Cho D, et al. (2000) Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide- activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B. J Biol Chem 275: 32681-32687.
46. Karin M, Chang L (2001) AP-1-glucocorticoid receptor crosstalk taken to a higher level. J Endocrinol 169: 447-451. (Pubitemid 32536977)
47. Nissen RM, Yamamoto KR (2000) The glucocorticoid receptor inhibits NF kappa B by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 14: 2314-2329. (Pubitemid 30746014)
48. Sternberg EM (2006) Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat Rev Immunol 6: 318-328.
49. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P (2003) Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 9: 213-219. (Pubitemid 36227724)
50. Li M, Pascual G, Glass CK (2000) Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol 20: 4699-4707. (Pubitemid 30396117)
51. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, et al. (2005) A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437: 759-763. (Pubitemid 41486547)
52. Lee CH, Curtiss LK (2003) Transcriptional repression of atherogenic inflammation: Modulation by PPAR delta (vol 302, pg 453, 2003). Science 302: 1153. (Pubitemid 37421001)
53. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, et al. (2007) Macrophage-specific PPAR gamma controls alternative activation and improves insulin resistance. Nature 447: 1116-U1112. (Pubitemid 47014427)
54. Vats D, Mukundan L, Odegaard JI, Zhang L, Smith KL, et al. (2006) Oxidative metabolism and PGC-1 beta attenuate macrophage-mediated inflammation. Cell Metabolism 4: 255-1255 (Pubitemid 43942258)
55. Gosset P, Charbonnier AS, Delerive P, Fontaine J, Staels B, et al. (2001) Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells. Eur J Immunol 31: 2857-2865. (Pubitemid 32994536)
56. Escarcega RO, Fuentes-Alexandro S, Garcia-Carrasco M, Gatica A, Zamora A (2007) The transcription factor nuclear factor-kappa B and cancer. Clin Oncol (R Coll Radiol) 19: 154-161. (Pubitemid 46172840)
57. Stathopoulos GT, Zhu Z, Everhart MB, Kalomenidis I, Lawson WE, et al. (2006) Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion. Am J Respir Cell Mol Biol 34: 142-150. (Pubitemid 43202460)
58. Gardner OS, Dewar BJ, Earp HS, Samet JM, Graves LM (2003) Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signaling on epidermal growth factor receptor transactivation. J Biol Chem 278: 46261-46269. (Pubitemid 37452196)
59. Pozzi A, Ibanez MR, Gatica AE, Yang S, Wei S, et al. (2007) Peroxisomal proliferator-activated receptor-alpha-dependent inhibition of endothelial cell proliferation and tumorigenesis. J Biol Chem 282: 17685-17695. (Pubitemid 47100312)
60. Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410: 37-40. (Pubitemid 32225829)
61. Furuhashi M, Hotamisligil GS (2008) Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 7: 489-503. (Pubitemid 351767117)
62. Wolfrum C, Borrmann CM, Borchers T, Spener F (2001) Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha- and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proc Natl Acad Sci U S A 98: 2323-2328. (Pubitemid 32209481)
63. Schachtrup C, Emmler T, Bleck B, Sandqvist A, Spener F (2004) Functional analysis of peroxisome-proliferator-responsive element motifs in genes of fatty acid-binding proteins. Biochem J 382: 239-245. (Pubitemid 39141587)
64. Tan N-S, Shaw NS, Vinckenbosch N, Liu P, Yasmin R, et al. (2002) Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Mol Cell Biol 22: 5114-5127. (Pubitemid 34700702)
65. Ulrichs T, Porcelli SA (2000) CD1 proteins: targets of T cell recognition in innate and adaptive immunity. Rev Immunogenet 2: 416-432. (Pubitemid 32041165)
66. Huynh H, Servant N, Chalifour LE (2007) Ubiquinol-cytochrome-c reductase 7.2 kDa protein of mitochondrial complex III is steroid-responsive and increases in cardiac hypertrophy and hypertension. Can J Physiol Pharmacol 85: 986-996.
67. Trumpower BL (1990) The protonmotive Q-cycle: energy transduction by coupling of proton translocation to electron-transfer by the cytochrome-bc1 complex. J Biol Chem 265: 11409-11412. (Pubitemid 20219292)
68. Mitchell P (1975) The protonmotive Q cycle: a general formulation. FEBS Lett 59: 137-139.
69. Skulachev VP (1998) Cytochrome c in the apoptotic and antioxidant cascades. FEBS Lett 423: 275-280. (Pubitemid 28129349)
70. Nishi H, Inagi R, Kato H, Tanemoto M, Kojima I, et al. (2008) Hemoglobin is expressed by mesangial cells and reduces oxidant stress. J Am Soc Nephrol 19: 1500-1508.
71. - in knockout mouse red cells expressing human HbC. Blood Cells Mol Dis 27: 69-70.
72. Romero JR, Suzuka SM, Nagel RL, Fabry ME (2004) Expression of HbC and HbS, but not HbA, results in activation of K-Cl cotransport activity in transgenic mouse red cells. Blood 103: 2384-2390. (Pubitemid 38326262)
73. Pleger ST, Harris DM, Shan C, Vinge LE, Chuprun JK, et al. (2008) Endothelial S100A1 modulates vascular function via nitric oxide. Circ Res 102: 786-794.
74. Ikura M, Osawa M, Ames JB (2002) The role of calcium-binding proteins in the control of transcription: structure to function. Bioessays 24: 625-636. (Pubitemid 34780350)
75. Phillips SE, Vincent P, Rizzieri KE, Schaaf G, Bankaitis VA, et al. (2006) The diverse biological functions of phosphatidylinositol transfer proteins in eukaryotes. Crit Rev Biochem Mol Biol 41: 21-49. (Pubitemid 43214656)
76. Routt SM, Bankaitis VA (2004) Biological functions of phosphatidylinositol transfer proteins. Biochem Cell Biol 82: 254-262. (Pubitemid 38580886)
77. Sugita S (2008) Mechanisms of exocytosis. Acta Physiol (Oxf) 192: 185-193. (Pubitemid 351160988)
78. Kültz D (2005) Molecular and evolutionary basis of the cellular stress response. Annu Rev Physiol 67: 225-257. (Pubitemid 40404492)
79. Yaqoob P (2003) Lipids and the immune response: from molecular mechanisms to clinical applications. Curr Opin Clin Nutr Metab Care 6: 133-150. (Pubitemid 40674517)
80. Cristea IM, Degli Esposti M (2004) Membrane lipids and cell death: an overview. Chem Phys Lipids 129: 133-160. (Pubitemid 38476987)
81. Danielpour D, Song K (2006) Cross-talk between IGF-I and TGF-beta signaling pathways. Cytokine Growth Factor Rev 17: 59-74. (Pubitemid 43117516)
82. Xie L, Bourne PE (2005) Functional coverage of the human genome by existing structures, structural genomics targets, and homology models. PLoS Comp Biol 1: e31. doi:10.1371/journal.pcbi.0010031.
83. Strömbergsson H, Kryshtafovych A, Prusis P, Fidelis K, Wikberg JES, et al. (2006) Generalized modeling of enzyme-ligand interactions using proteochemometrics and local protein substructures. Proteins 65: 568-579. (Pubitemid 44583208)
84. Shulman-Peleg A, Nussinov R, Wolfson HJ (2004) Recognition of functional sites in protein structures. J Mol Biol 339: 607-633. (Pubitemid 38625909)
85. Gold ND, Jackson RM (2006) SitesBase: a database for structure-based protein-ligand binding site comparisons. Nucleic Acids Res 34: D231-234.
86. Gold ND, Jackson RM (2006) A searchable database for comparing protein-ligand binding sites for the analysis of structure-function relationships. J Chem Inf Model 46: 736-742.
87. Schmitt S, Kuhn D, Klebe G (2003) A new method to detect related function among proteins independent of sequence and fold homology. J Mol Biol 323: 387-406. (Pubitemid 35283699)
88. Kuhn D, Weskamp N, Schmitt S, Hullermeier E, Klebe G (2006) From the similarity analysis of protein cavities to the functional classification of protein families using cavbase. J Mol Biol 359: 1023-1044. (Pubitemid 43842050)
89. Weskamp N, Kuhn D, Hullermeier E, Klebe G (2004) Efficient similarity search in protein structure databases by k-clique hashing. Bioinformatics 20: 1522-1526. (Pubitemid 39023156)
90. Jambon M, Imberty A, Deleage G, Geourjon C (2003) A new bioinformatic approach to detect common 3D sites in protein structures. Proteins 52: 137-145. (Pubitemid 36828938)
91. Ivanisenko VA, Pintus SS, Grigorovich DA, Kolchanov NA (2004) PDBSiteScan: a program for searching for active, binding and posttranslational modification sites in the 3D structures of proteins. Nucleic Acids Res 32: W549-W554. (Pubitemid 38997394)
92. Kinoshita K, Furui J, Nakamura H (2001) Identification of protein functions from a molecular surface database, eF-site. J Struct Funct Genomics 2: 9-22.
93. Kinoshita K, Nakamura H (2003) Identification of protein biochemical functions by similarity search using the molecular surface database eF-site. Protein Sci 12: 1589-1595. (Pubitemid 36910039)
94. Binkowski TA, Freeman P, Liang J (2004) pvSOAR: detecting similar surface patterns of pocket and void surfaces of amino acid residues on proteins. Nucleic Acids Res 32: W555-W558. (Pubitemid 38997395)
95. Tseng YY, Dundas J, Liang J (2009) Predicting protein function and binding profile via matching of local evolutionary and geometric surface patterns. J Mol Biol 387: 451-464.
96. Smith TF, Waterman MS (1981) Identification of common molecular subsequences. J Mol Biol 147: 195-197.
97. Binkowski TA, Adamian L, Liang J (2003) Inferring functional relationships of proteins from local sequence and spatial surface patterns. J Mol Biol 332: 505-526. (Pubitemid 37013514)
98. Laskowski RA, Watson JD, Thornton JM (2005) Protein function prediction using local 3D templates. J Mol Biol 351: 614-626. (Pubitemid 41021944)
99. Watson JD, Laskowski RA, Thornton JM (2005) Predicting protein function from sequence and structural data. Curr Opin Struct Biol 15: 275-284. (Pubitemid 40826446)
100. Fukunishi Y, Kubota S, Kanai C, Nakamura H (2006) A virtual active compound produced from the negative image of a ligand-binding pocket, and its application to in-silico drug screening. J Comput Aided Mol Des 20: 237-248. (Pubitemid 44317516)
101. Tanrikulu Y, Schneider G (2008) Pseudoreceptor models in drug design: bridging ligand- and receptor-based virtual screening. Nat Rev Drug Discov 7: 667-677.
102. Tortora G, Bianco R, Daniele G (2004) Strategies for multiple signalling inhibition. J Chemother 16 (Suppl 4): 41-43. (Pubitemid 40065279)
103. Xie L, Xie L, Bourne PE (2009) A unified statistical model to support local sequence order independent similarity searching for ligand binding sites and its application to genome-based drug discovery. Bioinformatics; In press.
104. Shindyalov IN, Bourne PE (1998) Protein structure alignment by incremental combinatorial extension (CE) of the optimal path. Protein Eng 9: 739-747. (Pubitemid 28434482)
105. Dundas J, Zheng O, Tseng J, Binkowski B, Turpaz Y, et al. (2006) CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated resiudes. Nucleic Acids Res 34: W116-W118. (Pubitemid 44529746)
106. Shoichet BK, Irwin JJ (2005) ZINC - a free database of commercially available compounds for virtual screening. J Chem Inf Model 45: 177-182.